Dapsone-13C12

• Description:

  Dapsone-13C12 is the 13C12 labeled Dapsone (HY-B0688) . Dapsone (4,4′-Diaminodiphenyl sulfone) is an orally active and blood-brain penetrant sulfonamide antibiotic with bacteriostatic, antimycobacterial and antiprotozoal activities. Dapsone exerts effective antileprosy activity and inhibits folate synthesis in cell extracts of M. leprae. Dapsone is used for dermatologic disorder research, including leprosy, dermatitis herpetiformis, acne vulgaris et al[1][2][3][4][5].

• Product Name Alternative:

  4,4′-Diaminodiphenyl sulfone-13C12; DDS-13C12

• UNSPSC:

  12352005

• Hazard Statement:

  H302

• Target:

  Antibiotic; Bacterial; Isotope-Labeled Compounds; Parasite; Reactive Oxygen Species (ROS)

• Type:

  Isotope-Labeled Compounds

• Related Pathways:

  Anti-infection; Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB; Others

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Infection; Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/dapsone-13c12.html

• Solubility:

  10 mM in DMSO

• Smiles:

  O=S ([13C]1=[13CH][13CH]=[13C] ([13CH]=[13CH]1) N) ([13C]2=[13CH][13CH]=[13C] ([13CH]=[13CH]2) N) =O

• Molecular Formula:

  13C12H12N2O2S

• Molecular Weight:

  260.21

• Precautions:

  P264-P270-P330-P501

• References & Citations:

  [1]D Voeller, et al. Interaction of Pneumocystis carinii dihydropteroate synthase with sulfonamides and diaminodiphenyl sulfone (dapsone) .J Infect Dis. 1994 Feb;169 (2) :456-9.|[2]Dapsone, Drug.com|[3]Esther Moreno, et al. Evaluation of Skin Permeation and Retention of Topical Dapsone in Murine Cutaneous Leishmaniasis Lesions.Pharmaceutics. 2019 Nov 13;11 (11) :607.|[4]Y I Zhu, et al. Dapsone and sulfones in dermatology: overview and update. J Am Acad Dermatol|[5]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53 (2) :211-216.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Isotope-Labeled Compounds

• Clinical Information:

  No Development Reported

• CAS Number:

  1632119-29-9